Dutasteride in the treatment of hormone refractory prostate cancer;Trattamento con dutasteride nel tumore prostatico ormonerefrattario

Minerva Urologica e Nefrologica

Volumn 60, Issue 2, 2008, Pages 71-76

  Arena, F ^a,b  

^a Ospedale S Maria   (Italy)

^b NONE   (Italy)

Author keywords

Androgen antagonists; Prostatic neoplasms; Prostatic neoplasms, therapy

Indexed keywords

ANTIANDROGEN; DOCETAXEL; DUTASTERIDE; HYDROCORTISONE; KETOCONAZOLE; PREDNISONE;

ARTICLE; BONE LESION; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DYSPEPSIA; FOLLOW UP; HUMAN; MALE; PROSTATE CANCER; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AZASTEROIDS; ENZYME INHIBITORS; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 47149087354     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Petrow, V. The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications. Prostate 1986;9:343-7.
3. Crawford ED, Eisenberg MA, McLeod DG, Saulding JT, Benson R, Dorr FA et al. A controlled trial of leuprolide with and without flutamide in prostate carcinoma. N Engl J Med 1989;321:419-24.
4. Eisemberg MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
5. Assikis VJ, Simons JW. Novel therapeutic strategies for androgen-independent prostate cancer: an update. Semin Oncol 2004;31:26-32.
6. Scher HI, Kell WK, Flutamide withdrawal syndrome: its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 1993;11:1566-72.
7. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000;89:2570-6.
8. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:3705-12.
9. Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
10. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
11. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentration in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007;10:149-54.
12. Span PN, Völler MC, Smals AG, Sweep FG, Schalken JA, Feneley MR et al. Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase isozyme enzymatic activity in the human prostate. J Urol 1999;161:332-7.
13. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP et al. Differential alteration in 5-alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63:231-9.
14. Andriole G, Humphrey P, Ray P, Gleave M, Trachtenberg J, Thomas L et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regresion in prostate cancer. J Urol 2004;172:915-9.
15. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK et al. Mutation of the androgen-receptor genein metastatic androgen-indepndent prostate cancer. N Engl J Med 1995;332:1393-8.
16. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM et al. Increased expression of gens converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
17. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006;12:4072-9.
18. Heemers HV, Verhoeven G, Swinnen JV. Androgen activation of the SREBP pathway: Current insights. Mol Endocrinol 2006;20:2265-77.
19. Schmidt LJ, Ballman KV, Tindall DJ. Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. Prostate 2007;67:1111-20.